A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. Methods: Data were pooled from 6 clinical studies consisting of 335 patients with solid tumours or haematological malignancies administered pevonedistat alone or in combination with azacitidine, docetaxel, carboplatin + paclitaxel, or gemcitabine.
| INTRODUCTION
Protein degradation by the ubiquitin proteasome system (UPS) is necessary for the regulation of a broad array of cellular processes, including: cell-cycle division; DNA repair, growth and differentiation; quality control; and regulation of membrane receptors and ion channels. Defects in the system result in the pathogenesis of many cancers and numerous other diseases, including Alzheimer's disease, Parkinson's disease, Huntington disease, prion-like lethal disorders, cystic fibrosis, Angelman's syndrome and Liddle syndrome. 1 Drugs targeting the UPS have the potential to improve the outcome of many of these diseases, especially malignant conditions. The neddylation pathway that conjugates neural precursor cellexpressed, developmentally downregulated 8 (NEDD8) to the cullin-RING ligases (CRLs), the largest subfamily of the E3 ubiquitin ligases, is controlled by NEDD8-activating enzyme (NAE). 2 CRLs control the proteasomal degradation of proteins with roles in cell cycle progression, DNA replication and signal transduction. 3 CRL ligase function is dependent on NEDD8 conjugation, and therefore NAE is critical in regulating CRL activity. 2 Pevonedistat (TAK-924; formerly MLN4924) is an investigational, first-in-class, small-molecule NAE inhibitor. 4 Pevonedistat covalently binds with NEDD8 to form a pevonedistat-NEDD8 adduct that prevents NEDD8 conjugation to CRLs and thus results in CRL substrate accumulation and apoptotic cell death. 4, 5 Single-agent pevonedistat has been studied in Phase I clinical trials in patients with advanced nonhaematological malignancies (Study C15001, NCT00677170); lymphoma and multiple myeloma (Study C15002, NCT00722488); acute myelogenous lymphoma (AML), myelodysplastic syndromes (MDS), or acute lymphoblastic leukaemia (Study C15003, NCT0091106); and melanoma (Study C15005, NCT01011530). Combination therapy with azacitidine was studied in AML patients (Study C15009, NCT01814826), and patients with solid tumours in combination with either docetaxel, carboplatin + paclitaxel, or gemcitabine (Study C15010, NCT01862328).
The pharmacokinetics (PK) of pevonedistat, following single and multiple intravenous (IV) administrations, has been evaluated based on data from 4 of the Phase I studies reported here. [6] [7] [8] [9] Plasma concentrations of pevonedistat declined in a bi-exponential manner at the end of a 1-hour IV infusion, with little or no notable drug accumulation The clinical development programme for pevonedistat has evaluated its safety and efficacy across a range of cancer indications, including solid tumours and haematological malignancies. Clinical trials have evaluated pevonedistat both as a single agent and in combination with standard-of-care agents. In solid tumours, combinations with 3 distinct chemotherapy regimens were evaluated (docetaxel, carboplatin + paclitaxel, gemcitabine) aimed at possible future development in solid tumour indications where these chemotherapy backbones may represent standards of care. 10 In AML and MDS, pevonedistat has been evaluated in combination with the hypomethylating agent azacitidine, 11, 12 and is currently in the pivotal phase of clinical investigation in higher risk MDS and low blast AML in the PANTHER Phase III trial (NCT 03268954).
The objectives of this population PK (PPK) analysis were to describe IV pevonedistat PK using nonlinear mixed effects modelling in patients with solid or haematological malignancies and identify potential predictors of interpatient variability in pevonedistat exposures when given alone or in combination with standard-of-care chemotherapy.
| METHODS

| Clinical studies and patients
Adult patients from 4 single-agent Phase I and 2 combination Phase Ib dose-escalation clinical studies were included in the analysis (Table 1 ).
In the 4 Phase I studies in patients with solid tumours or haematological malignancies, single-agent pevonedistat was administered via a 1hour IV infusion at dose levels of 25-278 mg/m 2 , across 6 different dosing schedules, in 21-day cycles. [6] [7] [8] 13 In the Phase Ib study C15009 in treatment-naïve elderly (≥60 years) AML patients considered unlikely to benefit from conventional chemotherapy, 20 or
What is already known about this subject • Pevonedistat (TAK-924; formerly MLN4924) is an investigational, first-in-class, small-molecule NEDD8activating enzyme inhibitor in development for treatment of solid tumours or haematological malignancies.
• Several clinical studies have characterized the pharmacokinetics of pevonedistat administered alone or in combination with standard of care therapies in patients with solid tumours or haematological malignancies. 30 mg/m 2 pevonedistat was administered via a 1-hour IV infusion on days 1, 3 and 5 in combination with 75 mg/m 2 azacitidine (IV/subcutaneous) on days 1-5, 8 and 9 in 28-day cycles. 14 
What this study adds
| Bioanalytical methods
Blood samples were collected before and at predetermined specific time points after the start of pevonedistat infusion during the first treatment cycle of each study. Samples were analysed for pevonedistat plasma concentrations using validated liquid chromatography-tandem mass spectrometry methods as described previously. 7 The dynamic range was 0.0500-25.0 ng/mL for the low range method (precision [%CV]: 3.1-5.1%; accuracy [%bias]: −1.8% to −0.5%) and
1.00-500 ng/mL for the medium range method (precision: 2.5-3.1%; accuracy: −1.5 to 0.0%). A nonparametric unstratified bootstrap 18 was conducted on the PPK model using the full dataset to determine the confidence intervals of the parameters for the final models. Parameters were evaluated to ensure the 95% confidence intervals did not include zero.
| Population PK model development and validation
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY, 19 The parameter estimates of the final model are shown in Table 3 along with the results of a nonparametric bootstrap. The parameter where 160 mg was the approximate median dose) are provided in Panel A in Figure 3 shows the comparison of CL by patient sex. 
| DISCUSSION
Novel treatments are needed for cancer patients considered unfit for conventional chemotherapy. Pevonedistat is an investigational, firstin-class, small-molecule NAE inhibitor that is being studied for treatment of patients with solid or haematological malignancies. Characterization of the extent and sources of PK variability is a key objective in anticancer drug development, as it is important to inform posology across contexts of clinical use and patient-specific factors. 22 To this end, this analysis was conducted to identify the sources of variability in pevonedistat PK using a population modelling approach that pro- However, it is to be noted that the effect of severe renal impairment on pevonedistat PK is currently unknown and warrants evaluation as severe renal impairment can potentially impact nonrenal clearance of metabolized drugs. 23 Taken together, it can be concluded from this model-based analysis that mild or moderate renal impairment did not impact pevonedistat clearance, such that no dose modifications should be required for pevonedistat in these specific patient populations based on PK considerations. It should, however, be noted that there were only 5 patients with severe renal impairment in the analysis dataset (one patient was classified as severe at baseline, 4 other patients were classified as severe later), and as such the present analysis does not permit a definitive assessment of the effect of severe renal impairment on pevonedistat PK. The observed lack of effect of mild or moderate renal impairment on pevonedistat PK is consistent with the lack of appreciable renal clearance of pevonedistat, with a < 5% contribution to total systemic clearance based on the clinical mass balance study ( Millennium Pharmaceuticals, Inc. data on file).
| Pevonedistat in combination with other chemotherapy
| Effects of renal and hepatic impairment
| Effects of other covariates
Body weight was identified as an important predictor for pevonedistat clearance early in the covariate model development, but was supplanted by the normalized BSA from a practical standpoint, given that body weight and BSA are highly correlated and that BSA-based dosing was used in the clinical development program as traditionally utilized for cytotoxic intravenously administered small molecule anticancer agents like pevonedistat. Furthermore, the selection of BSA over body weight as the covariate was also supported by the good control of PK variability across the patient population demonstrated via simulation with BSA-based dosing ( Figure 5 ). Age (range 23-90 years) was also not identified as being predictive of pevonedistat PK. Sex and race had no apparent effects on pevonedistat PK. Disease type (haematological vs nonhaematological tumour) also had no apparent effects on pevonedistat PK.
| CONCLUSIONS
The PK pevonedistat in adult cancer patients was adequately described by a 2-compartment model with first order elimination. BSA was an important predictor of all pevonedistat PK parameters (CL, Vc, Q and Vp). The impact of BSA on CL justifies the use of BSA-based dosing.
ALB was found to impact Q, but did not affect the systemic clearance ≤2.5 × ULN), had no impact on pevonedistat PK.
